Cefiderocol treatment of Pseudomonas aeruginosa and extensively drug-resistant Acinetobacter baumannii retained spinal hardware infection causing reversible acute interstitial nephritis: Recto: Cefiderocol causing acute interstitial nephritis

Int J Infect Dis. 2021 Aug:109:108-111. doi: 10.1016/j.ijid.2021.06.035. Epub 2021 Jun 23.


Infections with extensively drug-resistant Acinetobacter baumannii (XDRAB) have limited therapeutic options. We report successful salvage treatment of XDRAB and Pseudomonas aeruginosa-infected retained spinal hardware with cefiderocol, despite the development of reversible acute interstitial nephritis after 32 days of treatment.

Keywords: Acute interstitial nephritis; Biofilm; Cefiderocol; Extensively drug-resistant Acinetobacter baumannii (XDRAB); MDR Gram-negative; Spinal hardware infection; Surgical site infection.

Publication types

  • Case Reports

MeSH terms

  • Acinetobacter baumannii*
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Cefiderocol
  • Cephalosporins / therapeutic use
  • Drug Resistance, Multiple, Bacterial
  • Humans
  • Microbial Sensitivity Tests
  • Nephritis, Interstitial* / drug therapy
  • Pharmaceutical Preparations*
  • Pseudomonas aeruginosa


  • Anti-Bacterial Agents
  • Cephalosporins
  • Pharmaceutical Preparations